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Renal transplantation confers improvement in quality of life and survival when compared to patients on dialysis. There is a
universal shortage of organs, and eﬀorts have been made to overcome this shortage by exploring new sources. One such area
is the use of kidneys containing small tumours after resection of the neoplasm. This paper looks at the current evidence in the
literature and reviews the feasibility of utilizing such a source.
1.Introduction
Renal transplantation is the optimal mode of treatment for
the patients with end stage renal failure. One of the major
problems for transplantation is the discrepancy between
the donor and recipient numbers with far less donor than
recipients. As a consequence, patients with renal failure have
to wait fora long time before they can be oﬀeredan allograft.
This situation is especially worse in some countries like
Japan, with small cadaver programme where the average
waiting time is 16 years [1].
A signiﬁcant number of patients die from the compli-
cations of chronic renal insuﬃciency on long-term dialysis
beforetheygetatransplant. This situationismoreimportant
especially in cases where chronic kidney disease has lead
to other medical problems and patient either die of the
complications or become too unwell for a transplant [2].
Various measures including the use of marginal donors
and use of kidneys from Maastricht category II non-heart-
beating donors (NHBD) [2] have been utilized to increase
the donor pool along with measures to improve and prolong
graft function and survival. In addition, increasingly elderly
donors are used, therefore increasing the risk of renal
malignancy.
Onepotentialarea,ﬁrstdescribedbyPenn[3]hasbeento
transplant kidneys after ex vivo resection of small tumours.
This was a very radical idea, because ﬁrstly, there has
been evidence of transmission of donor-derived malignancy
into recipient from the very early days of transplantation
[4]. Secondly as a general rule, organs from donors with
malignancies have not been used for the same fear with
some exceptions such as central nervoussystem tumours [5].
Surprisingly-outcomes of the patients described in Penn’s
series were not as bad as could have been anticipated.
The contemporary experience with partial nephrectomy
and its success for the treatment of small renal cell cancers
has lead to extrapolation of similar technique for the
management of allograft malignancy [6] albeit sporadically.
The purpose of this paper is to summarise the current
evidence with regards to the utilization of kidneys with
tumours for transplant and the use of conservative surgery
for allografts where possible.
2.MaterialandMethods/ReviewCriteria
Pubmed, medline, EMBASE and CINHAL were linked
searched for“renaltumour/tumor,”“kidneytumour/tumor,”
“allograft tumour/tumor,” “nephron sparing surgery,” “par-
tial nephrectomy,” and “transplant” to indentify potentially
relevant articles. Articles concerning the use of kidneys
after resection of renal tumour for transplant and partial2 International Journal of Nephrology
nephrectomy of allograft for renal tumours were selected.
References of the selected article were also searched to
identify further articles of interest.
3.Results
From the above-mentioned criteria of the literature search
the following diﬀerent types of case reports/case series were
identiﬁed which are discussed separately.
3.1. Use of Kidneys after Resection of Tumours. Normal
practice when confronted with a tumour of kidney on
procurement is to return it to the donor and not use any
other organs [7]. In cases of deceased donors it meant that
the contralateral kidney cannot be used as well because of
the concerns of micro metastasis and bilaterality of some of
the renal cell carcinomas (RCC).
Penn [3], reviewing the Cincinnati transplant tumour
registry (CTTR), described a total of 14 cases of ex vivo
resection of small renal cell cancers detected incidentally
followed by transplantation. Frozen section was employed,
and where margins were clear, kidneys were used although
it is not clear whether all of the tumour bearing kidneys
underwent frozen section. Of the cadaveric donors, the
contralateral kidneys, all of which appeared healthy, were
transplanted as well. Apart from these cases of renal carci-
nomas, there was one case of oncocytoma within the kidney
which was transplanted after resection. Of all the caseswhere
the tumour was adequately resected before transplantation
there was no recurrence in a followup ranging up to 210
months.
Buell et al. [7] presented 14 cases of transplantation after
renal tumour resection from the same database as used by
Penn. No recurrence has been noted up to a followup of
200 months. Median tumour size was 2.0cm (range 0.5–
4.0cm) and all were of low histological grade. They have
described two further cases since the initial data review with
no recurrence and good graft function.
A similar case series from Australia [8] only included
elderlyrecipientsorthosewithsigniﬁcantcomorbiditiesand
high chance of death without transplantation. Furthermore
the recipients had high levels of HLA mismatching with the
donors and were selected on the basis that if there was a
recurrence to occur, stopping immunosuppression may help
in tumour lysis by recipient’s immune response. 41 patients
received kidneys after ex vivo resection of tumour of which
10 were reported as benign lesion on histopathology. One
patient returned to dialysis after 30 months. 4 patients died
of unrelated causes. There was only one recurrence noted 9
years after transplantation out of the remaining 30 patients.
Notably this tumour recurrence was at a distance from the
initial resection site, this therefore may not be a tumour
recurrence butanotherprimary within a “ﬁeld” change renal
tissue. The patient refused any further treatment, and the
lesion has grown 0.2cm in 18 months since diagnosis. In
a followup study on these patients this group has recently
published long-term outcomes which are signiﬁcantly better
than wait-listed patients on dialysis and are comparable to
t h el i v eu n r e l a t e dt r a n s p l a n t s[ 9].
Mannami et al. [10] from Japan published a series
of 42 “restored” kidneys from live donors. Eight donors
with small renal cell carcinoma (<3.5cm) underwent donor
nephrectomyandexvivoresectionofthetumourfollowedby
transplantation of the kidney. Five patients were alive, three
with functioning grafts, two died with functioning grafts
from unrelated caused, and one was lost to followup. No
tumour recurrence has been noted in any of these patients.
Another 8 patients had donor nephrectomies which had
benign diseases of which 5 had partial resection and kidney
used for transplantation. Three recipients are alive with
functioning grafts, while four have gone back to dialysis
(after 3,18,51,73 months). One recipient died of unrelated
pathology.
There havealso been6case reports[11–16]ofliverelated
kidney donationwhen a tumour was detected incidentally in
or ex vivo and the kidney was transplanted after resection.
No recurrence has been noted in any of these cases with a
followup of up to more than 10 years.
3.2. Partial Nephrectomy for Tumours Diagnosed after Trans-
plantation. Renal cell carcinoma represents around 4.6% of
all the tumours in allograft recipients with only 10% of these
occurring in the allograft itself [3].
The othermain subgroup is when a tumourwas detected
after transplant. Again the standard practice here has been
to perform transplant nephrectomy [17]w i t ht h ep a t i e n t
invariably returning to dialysis and normally being put on
a waiting list for another transplant if feasible.
Until now, more than 50 cases of allograft renal cell
tumours have been described in the literature of which at
least 35 cases have had nephron sparing surgery (NSS) for
their allograft tumour [6, 11, 18–36]. Tumour sizes have
range, from 0.5 to 4.0cm although there have been two
case reports of larger (6–8cm) tumours all being successfully
treated with NSS [18, 19]. Postoperative followup is from
one month to more than 10 years with one recurrence 5
years after NSS in renal allograft [37]. This was in a 74 year
old recipient ﬁve years after initial transplant. A 2.4cm RCC
was incidentally detected without any evidence of distant
metastasis. It was treated with radical nephrectomy and
patient has been disease free on hemodialysis.
3.3. Contralateral Transplanted Kidney with a Renal Tumour
in Cadaveric Donor. These kidneys again are normally not
used as RCC can be bilateral especially the papillary subtype
[38]. Penn [3] has described 14 cases in which the con-
tralateral kidney was transplanted from patients with renal
tumour. One patient had recurrence in the allograft which
was removed for rejection. This patient died 75 months after
transplantation from a de novo cancer of one of his own
kidneys. The remaining patients did not have any recurrence
with a followup ranging from 0.5 to 153 months.
Nicol et al. [8] described 2 similar cases with no
recurrence. Barrou et al. [38] has described a case of two
allograft recipients from a single donor with tubulopapillaryInternational Journal of Nephrology 3
tumour(17mm) in theright kidney; only theleft kidneywas
utilizedfortransplantation. Shortlyaftertransplantation, the
recipient underwent an ultrasound (US) examination of the
allograft which did not reveal any tumour. 3 months later
a biopsy was done for rejection which revealed a poorly
diﬀerentiated tumour and the patient underwent radical
allograft nephrectomy. No additional chemotherapy was
given apart from discontinuation of immunosuppression
(prednisolone and azathioprine). Lymph nodes that had
been noted to be enlarged on CT scan disappeared two
month after nephrectomy. The patient underwent re trans-
plantation two years later and was disease free and dialysis
independent at 3 year followup. Another patient received the
heart transplant from the same donor but died from bony
metastasis from the renal cell carcinoma.
3.4. Accidental Transplantation. In at least 4 cases [3, 13,
20, 39] there have been accidental transplantation of RCC
mistaken as a benign pathology on procurement. Partial
nephrectomy/enucleation in all these cases was performed
before transplantation with adequate resection margins.
Routine histopathology revealed the resected tumour to be
malignant. All recipients retained the allograft because of
complete excision of the tumour and were kept under close
follow-up with no recurrence so far.
The cases where there have been transplantation of
tumour, either partially resected or unrecognized at the time
of transplant have resulted in disastrous outcomes [3, 38].
3.5. Miscellaneous. Manammi et al. [10] reported a series
of 8 patients who underwent nephrectomy for a distal
ureteric transitional cell carcinoma (TCC). One patient had
a recurrence of TCC after 15 months and was oﬀered graft
nephrectomy but opted for partial resection of ureteric
tumour to prevent returning to dialysis. He died three years
after partial resection from a squamous cell carcinoma of
lung with liver metastasis. His TCC also had squamous
metaplasia and a DNA study to determine exact origin
of primary tumour could not be established because of
inadequate tissue samples. The remaining patients were
either alive with functioning grafts or died of unrelated
causes.
3.6. Opinion of Patients and Transplant Specialists. Trans-
plantation of kidneys with cancers is a novel idea not only
among patients but also among the transplant community.
To be able to exploit this potential donor pool it is of utmost
importance that both the health care specalists; transplants
surgeons and nephrologists and the patients both donors
and recipients are comfortable with the idea of using such
kidneys. To determine this, structured questionnaires were
sent to focus group of patients on the North East renal
transplant waiting list, postnephrectomy patients for small
renal cancer, nephrologists and transplant surgeons in the
UK [40].
Results are shown in Table 1 and have a generally high
response rate. Those respondents that had lost their kidney,
removed for tumour, had the highest consent rate and
Table 1
Respondents Response rate Support use of
kidneys
Potential recipients on
waiting list 97% (113/116) 59% (67/113)
Previous nephrectomy
(potential donors) 100% (15/15) 93% (14/15)
Nephrologists 58% (94/161) 78% (73/94)
Transplant surgeons 66% (43/65) 72% (31/43)
patients potentially receiving such kidney the lowest. The
transplant surgeon and nephrologists had views somewhere
in between.
T h i ss u r v e yw a sd o n ei nU Kf r o mw h e r et h e r eh a v eb e e n
no case reports of using organs after removal of tumour and
but still the response was largely favourable. Given that since
thissurveytherehasbeenanincrease in totalnumberofsuch
organs being utilized, one can extrapolate that current belief
m a yb em o r ef a v o u r a b l e .
3.7. Role of Immunosuppression. One of the worries about
transplantation of tumour aﬀected kidneys is the potential
of tumour recurrence and growth in state of potential
immune inattention due the immunosuppressive therapy.
Renal cell carcinoma is known to be an immunogenic
tumour [21] but in the presence of immunosuppression, if
there was any transplantation of tumour cells in the host,
then the potential of continued growth will be higher in
a host with a compromised immune system. Furthermore,
immunosuppression in itself has been known to increase the
incidence of de novo malignancy [41, 42]. Because of these
concerns, an immunosuppressive agent with no potential
to increase de novo malignancy and better still to have
antitumour activities would probably be ideal. Rapamycin
has shown some promise as being a protective agent against
RCC progression [21, 43, 44].
4.Discussion
Incidence of RCC has increased in Western countries in
the last few years owing to the widespread use of US and
CT scanning [45, 46]. Most RCC are now picked up at an
early stage on investigations done for other reasons [47].
Furthermore the incidenceofRCCin allografts will continue
to increase as older people donate organs and graft survival
is improved by better immunosuppression. Longitudinal
studies have shown that many small tumours have a slow
growth pattern with low metastatic spread in tumours of
<3cm [48, 49]. Autopsy studies have shown that RCC are
present in 1%–20% of patients dying from unrelated cases,
meaning that many of the tumours will not prove to be
clinically signiﬁcant in the course of patient’s life [50, 51].
The gold standard treatment of resectable renal cell
carcinoma has been radical nephrectomy. Recent evidence
has changed this practice dramatically as survival after
radical nephrectomy (RN) and partial nephrectomy (PN)
has shown to be comparable [52]. Favourable outcomes4 International Journal of Nephrology
have been observed after NSS for <4cm RCCs and RN has
been described as “surgical overkill” [53] for these tumours.
Furthermore, local recurrence after NSS has been reported
to be <5% with recurrences mostly associated with large and
multifocal tumours.
A signiﬁcant risk of dying in patients on dialysis partic-
ularly in older patient has been one of the driving forces to
increase thenumber of kidneydonors. Renal transplantation
seems to confer a substantial survival advantage over dialysis
in patients with end-stage renal failure [2]. A signiﬁcant
number of patient accepted for dialysis are older patients,
who have a mortality risk of 25%. With longer waiting times
for a transplant, it is inevitable that many of the patients will
die before they can receive a transplant which would have
improved their quality of life and longevity[2]. Furthermore
16% to 23% of suspicious lesion resected from kidneys are
either benign or of low malignant potential [53–55]a n d
not using these kidneys with small tumours after partial
nephrectomy for transplantation seems wastage of precious
organs when one considers the beneﬁts of transplantation
over dialysis.
A suspicious lesion found at multiorgan retrieval should
have an excision biopsy and histological conﬁrmation of
clear margins before any of the organs can be transplanted.
A malignant lesion in the kidney when unrecognized and
transplanted continues to grow under the immunosup-
pression carries high risk of metastasis and can result in
fatal outcome. If the biopsy conﬁrms clear margins with
favourable histology then these organs could be used for
transplantation as risk of recurrence is very low. Situation is
more complex when it comes to using restored organs from
live (related/unrelated) renal cell carcinoma patients. Major
diﬀerence being that these are live cancer patients ﬁrst and
therefore must never be treated primarily as potential organ
donors to prevent any bias in treating their primary problem
which may lead to provision of less than optimal treatment
and ultimately harm to these patients [8,e d ] .T h i si ss h o w n
byTakahara et al.[56]intheirreviewofMannami etal.series
concerning ureteric carcinoma patient, where adherence to
standard practice for treating these tumours was not prac-
ticed with disastrous consequences. With changing trends,
radicalnephrectomyisnowregarded asanalternatestandard
of care to partial nephrectomy for T1a tumours when partial
nephrectomy is not technically feasible. This is due to the
comparable oncological outcomes after partial nephrectomy
and evidence that radical nephrectomy is an independent
predictor of low GFR. A positive outcome for a recipient
can never justify harm to a live donor; on the contrary, for
a transplant with a live donor to be regarded as a success
means that both the recipient and the donor have done well
[57]. Live related donors in Nicol et al. series were given
the options of observation, radical or partial nephrectomy
without any mention of the possibility of use of organs for
transplantation. Only after the patients had decided to opt
for radical nephrectomy possibility of domino donation was
discussed. This approach has the beneﬁt of making sure that
patientsmaketheirowndecisionswithout any pressure from
clinicians. Other important factor is to make sure that beliefs
of the clinician do not aﬀect patient’s treatment choices.
Importance of detailed informed consenting cannot be over
emphasised for the recipients of such restored organs. All the
relevant information especially ofthe origin oftheorgan and
potential of recurrence and associated risk must be discussed
fully and patients understanding checked.
Routine followup of the patients with annual US have
been suggested to make sure any recurrence is diagnosed as
early as possible. Tumours have been detected at early stage
with better outcomes because of regular followups. If one
kidney is found to have a tumour it is important that the
other kidney is closely followed up. It is easier in the live
donor setting when the donor can be carefully followed up
but in cadaveric donation there has to be a central database
for tracking the contralateral kidney [22]w h i c hm i g h tb e
transplanted into a recipient in a diﬀerent unit.
Immunosuppression is essential after transplant and
unfortunately this has been associated with the higher
incidence of cancers in recipients as opposed to the general
population [42]. Certain newer immunosuppressive agents
have anti tumour [58] activity and their use can, in theory
not only reduce the chances of recurrence but they can also
be used to treat patient should a recurrence occur.
Furthermore Human Tissue Act 2004 [59]t h a tc o v e r s
the use of organs for transplant in the UK allows anyone
to be a donor including live related and unrelated (altruistic
donor) provided there is adequate consenting. This means
that donation can also occur from patients suﬀering from
small renal cell carcinoma who have radical nephrectomy as
primary treatment provided measures are taken to ensure
that these patients are treated appropriately in the ﬁrst place
and both donor and recipients had given informed consent.
5.Conclusion
To increase the donor pool new sources have to be exploited.
Useofkidneysaftertumourresectionseemsafeasiblesource.
There are several important issues in using such marginal
and potentially dangerousorgans; patientsshould have com-
plete understanding of the implications of the type of organ
they are donatingand receiving, good surgical techniqueand
rigorous pathological testing of the resected tissue to make
sure there is no tumour left behind, regular followup with
adequate investigations, and a reliable organ tracking system
to investigate the recipient of contralateral organ should
one organ develop a recurrence. On top of this, transplant
surgeons and nephrologists should be comfortable in using
such organs. Usage of such organs is still in its infancy, and
for a much wider acceptance of this source to occur, there
is need for more research. One interesting area will be to
explore the new immunosuppressive agents with antiprolif-
erative properties on such recipients with the potential to
reduce recurrence rate or better still to prevent it altogether
while either replacing standard immunosuppressive agents
orreducingtheirrequireddosetherebyreducing sideeﬀects.
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